KR20250153865A - 크론병을 치료하는 방법에 사용하기 위한 미리키주맙 - Google Patents

크론병을 치료하는 방법에 사용하기 위한 미리키주맙

Info

Publication number
KR20250153865A
KR20250153865A KR1020257033226A KR20257033226A KR20250153865A KR 20250153865 A KR20250153865 A KR 20250153865A KR 1020257033226 A KR1020257033226 A KR 1020257033226A KR 20257033226 A KR20257033226 A KR 20257033226A KR 20250153865 A KR20250153865 A KR 20250153865A
Authority
KR
South Korea
Prior art keywords
mirikizumab
weeks
dose
endoscopic
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257033226A
Other languages
English (en)
Korean (ko)
Inventor
스튜어트 윌리엄 프리드리히
폴 프레드릭 폴락
제이 로렌스 터틀
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20250153865A publication Critical patent/KR20250153865A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020257033226A 2019-04-22 2020-04-15 크론병을 치료하는 방법에 사용하기 위한 미리키주맙 Pending KR20250153865A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962836910P 2019-04-22 2019-04-22
US62/836,910 2019-04-22
PCT/US2020/028273 WO2020219314A1 (en) 2019-04-22 2020-04-15 Mirikizumab for use in a method of treating crohn's disease
KR1020217034113A KR102869852B1 (ko) 2019-04-22 2020-04-15 크론병을 치료하는 방법에 사용하기 위한 미리키주맙

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217034113A Division KR102869852B1 (ko) 2019-04-22 2020-04-15 크론병을 치료하는 방법에 사용하기 위한 미리키주맙

Publications (1)

Publication Number Publication Date
KR20250153865A true KR20250153865A (ko) 2025-10-27

Family

ID=70554215

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257033226A Pending KR20250153865A (ko) 2019-04-22 2020-04-15 크론병을 치료하는 방법에 사용하기 위한 미리키주맙
KR1020217034113A Active KR102869852B1 (ko) 2019-04-22 2020-04-15 크론병을 치료하는 방법에 사용하기 위한 미리키주맙

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217034113A Active KR102869852B1 (ko) 2019-04-22 2020-04-15 크론병을 치료하는 방법에 사용하기 위한 미리키주맙

Country Status (21)

Country Link
US (1) US20220040299A1 (cg-RX-API-DMAC7.html)
EP (3) EP3958897B1 (cg-RX-API-DMAC7.html)
JP (3) JP7297930B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250153865A (cg-RX-API-DMAC7.html)
CN (2) CN119700968A (cg-RX-API-DMAC7.html)
AU (2) AU2020263238C1 (cg-RX-API-DMAC7.html)
BR (1) BR112021018930A2 (cg-RX-API-DMAC7.html)
DK (1) DK3958897T3 (cg-RX-API-DMAC7.html)
EA (1) EA202192532A1 (cg-RX-API-DMAC7.html)
ES (1) ES3075314T3 (cg-RX-API-DMAC7.html)
FI (1) FI3958897T3 (cg-RX-API-DMAC7.html)
IL (2) IL286818B2 (cg-RX-API-DMAC7.html)
LT (1) LT3958897T (cg-RX-API-DMAC7.html)
MA (1) MA55756A (cg-RX-API-DMAC7.html)
MX (1) MX2021012848A (cg-RX-API-DMAC7.html)
PT (1) PT3958897T (cg-RX-API-DMAC7.html)
SG (1) SG11202110619XA (cg-RX-API-DMAC7.html)
TW (2) TWI850365B (cg-RX-API-DMAC7.html)
UA (1) UA128657C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020219314A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202108094B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI850365B (zh) * 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法
KR20220066831A (ko) 2020-11-16 2022-05-24 엔브이에이치코리아(주) 습기경화형 접착제를 이용한 헤드라이닝 제조방법 및 이에 의해 제조되는 헤드라이닝

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20140049B1 (ar) 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
US20160031983A1 (en) 2013-03-15 2016-02-04 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
TWI811716B (zh) * 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
WO2018035330A1 (en) * 2016-08-19 2018-02-22 Janssen Biotech, Inc. Methods of treating crohn's disease with an anti-nkg2d antibody
EP3652539A4 (en) * 2017-07-10 2021-03-31 Rambam Med-Tech Ltd. ASSAYS FOR EVALUATING NEUTRALIZING ANTIBODIES IN ORGANIC MEDICINE TREATED PATIENTS AND USES THEREOF IN PERSONALIZED MEDICINE
TWI850365B (zh) * 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法

Also Published As

Publication number Publication date
CN113677366A (zh) 2021-11-19
BR112021018930A2 (pt) 2022-01-18
EP3958897A1 (en) 2022-03-02
JP7761614B2 (ja) 2025-10-28
ZA202108094B (en) 2025-05-28
TW202515610A (zh) 2025-04-16
AU2020263238B2 (en) 2023-08-17
AU2020263238C1 (en) 2024-02-22
WO2020219314A1 (en) 2020-10-29
EP4778573A2 (en) 2026-07-22
TWI850365B (zh) 2024-08-01
CN119700968A (zh) 2025-03-28
EP3958897B1 (en) 2026-05-06
PT3958897T (pt) 2026-07-17
AU2020263238A1 (en) 2021-11-04
SG11202110619XA (en) 2021-11-29
IL286818A (en) 2021-10-31
EA202192532A1 (ru) 2022-01-21
JP2025148449A (ja) 2025-10-07
EP4789714A2 (en) 2026-08-12
UA128657C2 (uk) 2024-09-18
KR102869852B1 (ko) 2025-10-14
NZ781127A (en) 2025-06-27
MX2021012848A (es) 2021-12-10
DK3958897T3 (da) 2026-07-20
JP7297930B2 (ja) 2023-06-26
US20220040299A1 (en) 2022-02-10
TW202103734A (zh) 2021-02-01
LT3958897T (lt) 2026-08-10
AU2023265759A1 (en) 2023-12-07
JP2023116680A (ja) 2023-08-22
ES3075314T3 (en) 2026-08-03
FI3958897T3 (fi) 2026-07-16
IL286818B1 (en) 2025-11-01
KR20210142704A (ko) 2021-11-25
MA55756A (fr) 2022-03-02
IL286818B2 (en) 2026-03-01
JP2022530397A (ja) 2022-06-29
CA3134587A1 (en) 2020-10-29
IL324048A (en) 2025-12-01

Similar Documents

Publication Publication Date Title
AU2023248103B2 (en) Methods of treating ulcerative colitis
Argollo et al. Novel therapeutic targets for inflammatory bowel disease
JP2025148449A (ja) クローン病を治療する方法に使用するためのミリキズマブ
CA3134587C (en) Mirikizumab for use in a method of treating crohn's disease
EA045979B1 (ru) Мирикизумаб для применения в способе лечения болезни крона
EA049081B1 (ru) Способы лечения язвенного колита

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)